NASDAQ: BIOABioage Labs Inc Stock
$17.05-0.19 (-1.1%)
Updated Apr 24, 2026
BIOA Price
$17.05
Fair Value Price
$6.17
Market Cap
$756.67M
52 Week Low
$3.67
52 Week High
$24.00
P/E
-7.61x
P/B
2.78x
P/S
52.85x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.00M
Earnings
-$80.61M
Gross Margin
100%
Operating Margin
-888.36%
Profit Margin
-896.1%
Debt to Equity
0.08
Operating Cash Flow
-$82M
Beta
1
Next Earnings
May 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
BIOA Overview
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BIOA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
A
BIOA
Ranked#51 of 52
Ranked#51 of 52
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.52 | A | |
| $33.23 | A | |
| $30.64 | A |
Be the first to know about important BIOA news, forecast changes, insider trades & much more!
BIOA News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BIOA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIOA ($17.05) is overvalued by 176.36% relative to our estimate of its Fair Value price of $6.17 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BIOA ($17.05) is not significantly undervalued (176.36%) relative to our estimate of its Fair Value price of $6.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BIOA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BIOA due diligence checks available for Premium users.
Valuation
BIOA fair value
Fair Value of BIOA stock based on Discounted Cash Flow (DCF)
Price
$17.05
Fair Value
$6.17
Overvalued by
176.36%
BIOA ($17.05) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BIOA ($17.05) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BIOA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BIOA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.61x
Industry
-158.5x
Market
35.57x
BIOA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.78x
Industry
1.59x
BIOA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BIOA's financial health
Profit margin
Revenue
$3.1M
Net Income
-$25.9M
Profit Margin
-842.9%
BIOA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BIOA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$294.9M
Liabilities
$22.8M
Debt to equity
0.08
BIOA's short-term assets ($286.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIOA's short-term assets ($286.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIOA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$28.3M
Investing
-$14.4M
Financing
$16.0M
BIOA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BIOA vs Pharmaceutical Stocks
Bioage Labs Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.